Roche move endorses Iteos’s Tigit widget

Roche’s decision to start a large pivotal program with the Tigit blocker tiragolumab has rekindled enthusiasm about this mechanism, notably sending Arcus’s stock up 70%. This might have overshadowed a third Tigit player, the private biotech Iteos, which nevertheless boasts of a surge of interest behind the scenes.